Healthcare / BiotechnologyNasdaqCM
$0.90
-0.14 (-13.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-9.7M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
547.1%
↑Gross Margin
N/A
•Debt/Equity
-0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-39.2M · FCF $-18.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-39.2M | $-39.2M | $-17.8M | $-535000.00 | $-4.9M | — |
| EBITDA | $-36.5M | $-36.5M | $-15.8M | $3.1M | $-4.9M | — |
| EPS | -1177.89 | -1177.89 | -38616.05 | -24617.89 | -20278.01 | — |
| Balance Sheet | ||||||
| Debt/Equity | -0.11 | -0.11 | -1.10 | -2.16 | -0.20 | — |
| Current Ratio | 0.34 | 0.34 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-18.0M | $-18.0M | $-9.7M | $-7.7M | $-2.3M | — |
| Returns | ||||||
| ROE | 547.1% | 547.1% | 262.1% | 117.1% | 48.4% | — |
| Valuation | ||||||
| EV/EBITDA | — | — | — | 124.40 | — | — |
| Growth & Yield | ||||||
| EPS Growth | 96.9% | 96.9% | -56.9% | -21.4% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-99.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-38616.05 → -1177.89
Residual
-99.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.